ArticlePharmaceutics2023
Interpenetrating Polymer Networks of Poly(2-hydroxyethyl methacrylate) and Poly(N, N-dimethylacrylamide) as Potential Systems for Dermal Delivery of Dexamethasone Phosphate.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
- Hydrogels of Poly(2-hydroxyethyl methacrylate) and Poly(N,N-dimethylacrylamide) Interpenetrating Polymer Networks as Dermal Delivery Systems for Dexamethasone.Pharmaceutics · 2025Article
- Recent Advances in Micro- and Nano-Drug Delivery Systems Based on Natural and Synthetic Biomaterials.Polymers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
In this study, a series of novel poly(2-hydroxyethyl methacrylate) (PHEMA)/poly(N,N'-dimethylacrylamide) (PDMAM) interpenetrating polymer networks (IPNs) were synthesized and studied as potential drug delivery systems of dexamethasone sodium phosphate (DXP) for dermal application. The IPN composition allows for control over its swelling ability as the incorporation of the highly hydrophilic PDMAM increases more than twice the IPN swelling ratio as compared to the PHEMA single networks, namely from ~0.5 to ~1.1. The increased swelling ratio of the IPNs results in an increased entrapment efficiency up to ~30% as well as an increased drug loading capacity of DXP up to 4.5%. X-ray diffraction (XRD) and differential scanning calorimetry (DSC) show the formation of a solid dispersion between the drug DXP and the polymer (IPNs) matrix. Energy-dispersive X-ray (EDX) spectroscopy shows an even distribution of DXP within the IPN structure. The DXP release follows Fickian diffusion with ~70% of DXP released in 24 h. This study demonstrates the potential of the newly developed IPNs for the dermal delivery of DXP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.